Biological role and therapeutic potential of IDH mutations in cancer
Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively …
The implications of IDH mutations for cancer development and …
Jun 15, 2021 · The oral pan-mutant IDH1 inhibitor BAY-1436032 reduces D-2HG levels, clears leukaemia blast cells, induces myeloid differentiation at the expense of leukaemia stem cells …
Vulnerability of IDH1 mutant cancers to histone deacetylase …
IDH1 mutant cells have a greater vulnerability to SAHA treatment. To test the implication of this SAHA-induced repair crisis on cell survival, we investigated whether IDH1 mutant cells have a …
Mutant IDH1 inhibition induces dsDNA sensing to activate
Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2-hydroxyglutarate, disrupting enzymes involved in epigenetics and other processes. A hallmark of IDH1-mutant solid tumors is T cell …
Mutant IDH1: An immunotherapeutic target in tumors - PMC
A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a …
Cancer-Associated IDH1 Promotes Growth and Resistance to ... - Cell …
May 30, 2017 · We show that genetic and pharmacologic inactivation of IDH1 decreases GBM cell growth, promotes a more differentiated tumor cell state, increases apoptosis in response to …
Biological Role and Therapeutic Potential of IDH Mutations ... - Cell …
Aug 13, 2018 · Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by …
Heating Up IDH-Mutant Gliomas - The New England Journal of …
Dec 4, 2024 · In short, the study by Wu and colleagues highlights the role of tumor cell–autonomous epigenetic defects in driving immune evasion to support the tumor …
Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug …
Apr 4, 2025 · Currently, the FDA has granted approval for the use of the small molecule inhibitor Ivosidenib (AG-120) in the treatment of IDH1-mutated AML and cholangiocarcinoma. Although …
Inhibition of mutant IDH1 promotes cycling of acute ... - Cell Press
Using a multi-allelic mouse model of IDH1-mutant AML, we demonstrate that the clinical IDH1 inhibitor AG-120 (ivosidenib) exerts cell-type-dependent effects on leukemic cells, promoting …